<!DOCTYPE html>
<html lang="zh" class="no-js">
<head>
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
<meta name="format-detection" content="telephone=no">
<meta content="email=no" name="format-detection">
<title>NEJM医学前沿</title>
<!-- Favicon -->
<link href="css/bootstrap.min.css" rel="stylesheet">

<link rel="stylesheet" type="text/css" href="css/font-t.css">
<link href="css/bootsnav.css" rel="stylesheet">
<link href="css/overwrite.css" rel="stylesheet">
<link href="css/style.css" rel="stylesheet">
<link rel="stylesheet" href="css/smartphoto.css">

<!-- HTML5 shim and Respond.js for IE8 support of HTML5 elements and media queries -->
<!--[if lt IE 9]>
	  <script src="js/html5shiv.min.js"></script>
	  <script src="js/respond.min.js"></script>
	<![endif]-->
</head>
<body >




<div  class="section">



  
<div class="clearfix"></div>

<!--article content-->
<div class="container"> 
  <!-- Start Arctile info -->
  
  
 <div class="row">
      <div class="col-sm-12 ">
        <h3  class="fw-300 news-title">博纳吐单抗和化疗在进展期急性淋巴细胞白血病治疗中的比较研究<br>
        </h3>
        <hr>
        <a class="auther_name" href="#auther_info"> Hagop Kantarjian M.D....</a>
                           <span class="a_date">2018.01.01 </span>
    
        
         <div style="clear:both; height:20px;"></div>
       
        
        <div id="article_relation">
        <div  class="article_relation">
       
          <div class="issues_qt_box box_99">
                <div class="qt_si" style="background:url(images/qt_s.png);">
                </div>
                <div class="issues_qt_icon">相关文章/视频</div><br>                      
                 <a href="">以初级医疗保健为基础的减重项目可缓解2型糖尿病</a>
         </div>
         <div style="clear:both;"></div>
         </div>
         
       </div>

                 <!-- tab 01 start -->   
                           
                            
                            

                            <!-- article list strat -->
         <div class="weeklycover_box">

          <div class="box_100">
                             
         

       <div id="nejm-article-content" class="nejm-article-content ">
        
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">在本项前瞻性随机3期临床试验中，21个国家101个中心的研究者纳入了处于以下任一阶段的Ph阴性前体B细胞ALL成人（年龄≥18岁）患者：对主要诱导治疗或挽救性强化联合化疗表现出难治性、首次缓解持续时间少于12个月即出现首次复发、二次或更多次复发或者接受了异体干细胞移植之后任意时间出现复发。附加的入选标准包括在骨髓中有多于5%的原始细胞和美国东部肿瘤协作组（Eastern Cooperative Oncology Group，ECOG）体能状态评分≤2（在一个5分的量表中评估，较高评分表明较高的失能程度）。主要的排除标准包括患有其他活动性癌症、有临床意义的中枢神经系统病理状态、孤立性髓外肿瘤、自身免疫病、2级或更高级别的急性移植物抗宿主病（GVHD）或活动性慢性GVHD、随机分组之前12周内接受了异体干细胞移植、随机分组之前6周内接受了自体干细胞移植、随机分组之前2周内接受了化疗或放疗、随机分组之前4周内使用了免疫疗法或者正在接受研究性治疗。</span></p>
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">&nbsp;</span></p>
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文"><strong>试验监管</strong></span></p>
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">所有患者签署了知情同意书。本研究由安进公司与临床试验研究者合作设计。试验方案（包含统计学分析计划）在每个试验中心获得了研究审查委员会或独立伦理委员会批准，方案与本文全文都可在NEJM.org获取。前两位作者和最后一位作者在安进公司聘请的医学写作专员的协助下撰写了论文初稿。所有作者均参与了论文修订并可以获得试验数据。所有作者担保数据的准确性和完整性，并保证试验忠实于研究方案。作为安进公司雇员的两位作者完成了统计学分析并对稿件做出了贡献。一个由两位临床医师和一位生物统计学家组成的独立的数据和安全性监察委员会定期会面，审查由一位独立的统计学家提供的安全性和疗效数据。</span></p>
        <img src="http://www.nejmqianyan.cn/data/upload/20170309/1489037673870979.png" >
        
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">我们利用交互式语音应答系统，按照2∶1的比例将符合入选条件的患者随机分配到接受开放标签的博纳吐单抗治疗或标准化疗（补充附录图S1，可在NEJM.org获取）。随机分组按照年龄（＜35或≥35岁）、之前的挽救疗法（是或否）以及之前的异体干细胞移植（是或否）进行分层。每个试验组的患者要接受最多两个周期的诱导治疗；另外，在每个组中，有形态学缓解的患者（≤5%骨髓原始细胞）要接受最多三个周期的巩固治疗，并且有持续性形态学缓解的患者要接受多达12个月的维持治疗。</span></p>
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">使用博纳吐单抗的诱导和巩固治疗按照6周的周期给药；在每个周期内，患者有4周接受治疗（第1个诱导周期的第1周每日9 μg，之后每日28 μg，连续输液），另2周不接受治疗。使用博纳吐单抗的维持治疗每12周进行4周连续输液给药。博纳吐单抗组中筛查时有高肿瘤负荷的患者要在治疗开始前接受地塞米松，以预防细胞因子释放综合征（补充附录表S1）。博纳吐单抗组所有患者要在博纳吐单抗给药前接受地塞米松给药，以预防输液反应（补充附录表S1），并根据机构或国家指南接受鞘内注射，以预防中枢神经系统疾病。如果发生了神经系统事件或其他指定的不良事件，则必须中断或停止博纳吐单抗给药（进一步的细节在补充附录的剂量调整章节中提供）；研究中允许对接受标准化疗的患者做出剂量调整，但是未规定对特定事件做出剂量调整。化疗组患者接受了由研究者在四种治疗方案中选择的一种方案：氟达拉滨、大剂量阿糖胞苷和粒细胞集落刺激因子，联用或不联用蒽环类抗生素；大剂量阿糖胞苷为基础的治疗方案；大剂量甲氨蝶呤为基础的治疗方案；或氯法拉滨为基础的治疗方案（补充附录表S2）。研究方案规定的治疗可以在第一个周期之后随时停止，之后如果研究者确定干细胞移植对患者最为有益，患者可以接受干细胞移植。</span></p>
        <p style="text-indent: 2em;"><span class="font-size-content" label="正文">&nbsp;</span></p>
     
        
       
       
        
           
            

            <p><span style="color: rgb(51, 51, 51);">&nbsp;</span></p>

            <h6 class="article">参考文献</h6>
            <div class="about-content-full-box">
                    <p>1.&nbsp;Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003;4:299-309.</p><p>2.&nbsp;Russell JP, Powell DJ, Cunnane M, et al. The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. Oncogene 2000;19:5729-5735.</p><p>3.&nbsp;Tognon C, Knezevich SR, Huntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell 2002;2:367-376.</p><p>4.&nbsp;Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-1472.</p><p>5.&nbsp;Wiesner T, He J, Yelensky R, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014;5:3116-3116.</p><p>6.&nbsp;Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.</p><p>7.&nbsp;Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846-4846.</p><p>8.&nbsp;Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.</p><p>9.&nbsp;Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. May 28, 2009 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).</p><p>10.&nbsp;Skálová A, Vanecek T, Sima R, et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am J Surg Pathol 2010;34:599-608.</p><p>11.&nbsp;Bourgeois JM, Knezevich SR, Mathers JA, Sorensen PH. Molecular detection of the ETV6-NTRK3 gene fusion differentiates congenital fibrosarcoma from other childhood spindle cell tumors. Am J Surg Pathol 2000;24:937-946.</p><p>12.&nbsp;Doebele RC, Davis LE, Vaishnavi A, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015;5:1049-1057.</p><p>13.&nbsp;Drilon A, Li G, Dogan S, et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol 2016;27:920-926.</p><p>14.&nbsp;Drilon A, Nagasubramanian R, Blake JF, et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov 2017;7:963-972.</p><p>15.&nbsp;Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010;28:357-360.</p><p>16.&nbsp;Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012;4:120ra17-120ra17.</p><p>17.&nbsp;Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non–small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786-792.</p><p>18.&nbsp;Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 2015;373:726-736.</p>                 </div>



       </div>
      </div>     
   </div>
                            
         
                            <div style="clear:both;"></div>
                            <!-- article list end-->                          
                          </div> 
                          <!-- tab01 end -->
                        </div>
                   <!-- tab end -->
      </div>
  </div>
    <div class="clearfix"></div>
    <!-- End Arctile info --> 
    
  </div>
</div>
<!--article content-->
</div>
 

<script>window.jQuery || document.write('<script src="js/jquery-1.11.0.min.js"><\/script>')</script> 
<script src="js/bootstrap.min.js"></script> 
<script src="js/bootsnav.js"></script> 
<script src="js/sf/jquery-smartphoto.js?v=1"></script>
<script>
  
  //顶部可伸缩菜单

   //文章图片展示 smart phote
   $("#nejm-article-content img").each(function(){
     var url = $(this).attr("src");
     //var figurename=$(this).attr("title");
     //$(this).before("<a class='js-smartPhoto' data-caption='"+figurename+"' href='"+url+"'><img src='"+url+"' ></a>");
     $(this).before("<a class='js-smartPhoto'  href='"+url+"'><img src='"+url+"' ></a>");
     this.remove();

   });
      
   $(".js-smartPhoto").smartPhoto();

  
</script> 
<script src="js/js.js"></script>
</body>
</html>
